ClinicalTrials.gg
CompletedNCT00259740Updated Mar 15, 2017Results posted

Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab

A Phase 2 interventional study of DENOSUMAB in Relapsed or Plateau-Phase Multiple Myeloma, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-15.

Primary conditionMultiple MyelomaRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Myeloma
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Multiple Myeloma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
96
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 43 studies in Multiple Myeloma by Amgen — none open to participants now, none under way, none of them phase 3. Multiple Myeloma · Amgen.

Enrollment
22nd of 40
96 · median 101
Started
2005
with 2 others
Phase 2
10 of 43
none open now
Registered
4th of 43
by date

Among the 43 studies in Multiple Myeloma by Amgen, this one is the 22nd largest by enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2005, is one of 10 in phase 2, and was the 4th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

None of the 43 studies in Multiple Myeloma by Amgen is open now. The open studies under Multiple Myeloma, anywhere →

Who these studies take

Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 43 studies in Multiple Myeloma by Amgen as a file.
02

Study summary

The purpose of this study is to determine if denosumab is effective in the treatment of relapsed or plateau-phase multiple myeloma.

Read the detailed description

Patients who have relapsed myeloma have failed treatment regimens and have had disease progression following their last treatment regimen. Despite newer salvage therapies, their treatment options are limited and may include best supportive care and investigational therapy. Patients with plateau-phase myeloma have a stabilized serum M-protein level without further tumor regression despite continued treatment. Recent evidence suggests that their prognosis might improve with further reduction in serum M-protein or prolongation of time to disease progression (TTP). These patients are candidates for investigational agents that could further reduce tumor burden or increase TTP.

03

Conditions studied

  • Relapsed or Plateau-Phase Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma, Relapsed, Plateau-Phase
04

In context

Multiple Myeloma Reclassified

3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

This study's enrollment of 96 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Multiple Myeloma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age ≥ 18 years
  • clinical diagnosis of or plateau-phase multiple myeloma
  • (>0.5 g/dL) as determined by special blood tests
  • 0 or 1

Exclusion criteria

Exclusion Criteria:

  • newly diagnosed myeloma
  • non-secretory myeloma
  • plasma cell leukemia or plasma cell dyscrasia with POEMS syndrome
  • prior stem cell transplant
  • administration of oral or IV bisphosphonates within 2 weeks of enrollment to study

Other criteria also apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    Denosumab

    Drug: DENOSUMAB

Interventions

  • 120 mg administered subcutaneously on study days 1, 8, 15, and 29 and every 28 days thereafter. Each dose will be administered in two separate injections of 60 mg (1.0 mL) each.

07

What researchers measure

Primary outcomes

  1. Complete Response or Partial Response Based on M-Protein Assessments Only

    Complete response or partial response based on serum M-Protein assessments. Complete response is defined as absence of original M-protein in serum by immunofixation, and partial response is defined as ≥ 50% reduction from baseline in serum M-protein, both maintained for a minimum of 6 weeks.

    Time frame: Up to 18 months

Secondary outcomes

  1. Complete Response, Partial Response or Minimal Response Based on M-Protein Assessments Only

    Complete response, partial response or minimal response based on serum M-protein assessments. Complete and partial responses are as defined for the primary outcome measure. Minimal response is defined as 25 to 49% reduction from baseline in serum M-protein level, maintained for a minimum of 6 weeks.

    Time frame: Up to 18 months

  2. Complete Response Based on M-Protein Assessments Only

    Complete response based on M-protein assessments, as defined for the primary outcome measure.

    Time frame: Up to 18 months

08

Results

Posted Jan 6, 2011

Participant flow

Participants were enrolled from 13 February 2006 through 8 December 2006

Participant flow — Overall Study
MilestoneDenosumab 120 mg Q4W - Plateau-PhaseDenosumab 120 mg Q4W - Relapsed
Started4353
Received study medication4253
Completed00
Not completed4353
Withdrew: Physician decision11
Withdrew: Adverse event02
Withdrew: Withdrawal by subject26
Withdrew: Death11
Withdrew: Disease progression1936
Withdrew: Ongoing173
Withdrew: Other30
Withdrew: Requirement for alternative therapy04

Outcome measures

PrimaryComplete Response or Partial Response Based on M-Protein Assessments Only

Complete response or partial response based on serum M-Protein assessments. Complete response is defined as absence of original M-protein in serum by immunofixation, and partial response is defined as ≥ 50% reduction from baseline in serum M-protein, both maintained for a minimum of 6 weeks.

Time frame:
Up to 18 months
Reported as:
Number · Participants
Complete Response or Partial Response Based on M-Protein Assessments Only
ParticipantsDenosumab 120 mg Q4W - Plateau-PhaseDenosumab 120 mg Q4W - Relapsed
Complete Response or Partial Response Based on M-Protein Assessments Only00
SecondaryComplete Response, Partial Response or Minimal Response Based on M-Protein Assessments Only

Complete response, partial response or minimal response based on serum M-protein assessments. Complete and partial responses are as defined for the primary outcome measure. Minimal response is defined as 25 to 49% reduction from baseline in serum M-protein level, maintained for a minimum of 6 weeks.

Time frame:
Up to 18 months
Reported as:
Number · Participants
Complete Response, Partial Response or Minimal Response Based on M-Protein Assessments Only
ParticipantsDenosumab 120 mg Q4W - Plateau-PhaseDenosumab 120 mg Q4W - Relapsed
Complete Response, Partial Response or Minimal Response Based on M-Protein Assessments Only00
SecondaryComplete Response Based on M-Protein Assessments Only

Complete response based on M-protein assessments, as defined for the primary outcome measure.

Time frame:
Up to 18 months
Reported as:
Number · Participants
Complete Response Based on M-Protein Assessments Only
ParticipantsDenosumab 120 mg Q4W - Plateau-PhaseDenosumab 120 mg Q4W - Relapsed
Complete Response Based on M-Protein Assessments Only00

Adverse events

Collected over up to 1 year 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Denosumab 120 mg Q4W - Relapsed—14/53 (26.4%)38/53 (71.7%)
Denosumab 120 mg Q4W - Plateau-Phase—6/42 (14.3%)32/42 (76.2%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventDenosumab 120 mg Q4W - RelapsedDenosumab 120 mg Q4W - Plateau-Phase
AnaemiaBlood and lymphatic system disorders2/530/42
ThrombocytopeniaBlood and lymphatic system disorders2/530/42
Multiple myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/530/42
Renal failureRenal and urinary disorders2/530/42
Intestinal obstructionGastrointestinal disorders0/531/42
Intestinal perforationGastrointestinal disorders0/531/42
Haemophilus infectionInfections and infestations0/531/42
PneumoniaInfections and infestations1/531/42
Septic shockInfections and infestations0/531/42
HypoglycaemiaMetabolism and nutrition disorders0/531/42
Most frequent other events
Showing 10 of 35
Most frequent other events
EventDenosumab 120 mg Q4W - RelapsedDenosumab 120 mg Q4W - Plateau-Phase
Upper respiratory tract infectionInfections and infestations9/5312/42
FatigueGeneral disorders8/538/42
HeadacheNervous system disorders4/538/42
Pain in extremityMusculoskeletal and connective tissue disorders3/537/42
AnaemiaBlood and lymphatic system disorders8/533/42
DiarrhoeaGastrointestinal disorders7/536/42
ArthralgiaMusculoskeletal and connective tissue disorders7/533/42
Back painMusculoskeletal and connective tissue disorders7/534/42
Oedema peripheralGeneral disorders0/535/42
NauseaGastrointestinal disorders6/534/42

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Denosumab 120 mg Q4W - Plateau-PhaseDenosumab 120 mg Q4W - RelapsedTotal
Mean61.1 ± 11.462.9 ± 9.262.1 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)Denosumab 120 mg Q4W - Plateau-PhaseDenosumab 120 mg Q4W - RelapsedTotal
Female261339
Male174057
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Denosumab 120 mg Q4W - Plateau-PhaseDenosumab 120 mg Q4W - RelapsedTotal
Caucasian353974
African American4711
Hispanic or Latino134
Other347
09

Study locations

No study locations are listed for this record.

10

References and documents

Publications

  • Vij R, Horvath N, Spencer A, Taylor K, Vadhan-Raj S, Vescio R, Smith J, Qian Y, Yeh H, Jun S. An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am J Hematol. 2009 Oct;84(10):650-6. doi: 10.1002/ajh.21509. PubMed 19714603 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2005, a primary completion of Aug 2007 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 3 years 5 months after primary completion. A results delay was requested in Nov 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2005
First posted
Dec 1, 2005
Start
Nov 2005
Primary completionActual
Aug 2007
CompletionActual
Dec 2011
Results delay requested
Nov 23, 2009
Results first posted
Jan 6, 2011
Last update
Mar 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00259740
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Dec 1, 2005
Start date
Nov 2005
Primary completion
Aug 2007
Completion
Dec 2011
Results posted
Jan 6, 2011
Last update
Mar 15, 2017

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion